Neue Entwicklungen auf dem Gebiet der genetischen Nierenerkrankungen

Zusammenfassung

Das bessere Verständnis genetischer Nierenerkrankungen hat in den letzten zehn Jahren einen immensen Wissenszuwachs über grundlegende Funktionsmechanismen der Niere erbracht. Einblicke in pathophysiologische Grundprinzipien häufiger, teils vererbter, teils erworbener Nierenerkrankungen konnten dabei durch die Erforschung seltener genetischer Erkrankungen gewonnen werden und dienen nun als Ausgangspunkt zukünftiger Therapien. So sind für die sehr häufige autosomal dominante polyzystische Nierenerkrankung aufgrund der Ergebnisse aus der Grundlagenforschung bereits verschiedene multizentrische klinische Studien etabliert worden. Zunehmend zeigt sich außerdem der Einfluss genetischer Aspekte bei häufigen Nierenerkrankungen wie der diabetischen Nephropathie. Der vorliegende Artikel gibt einen Überblick über wesentliche aktuelle Entwicklungen auf dem Gebiet der genetischen Nierenerkrankungen.

Abstract

The improved understanding of genetic kidney diseases has given rise to a more detailed understanding of kidney function within the last decade. Insights into the pathophysiological principles of frequent kidney diseases – partly inherited, partly acquired – have been obtained by the investigation of rare genetic disorders and can now serve as a starting point for the development of novel therapeutic strategies. In this way various clinical multicenter trials, which are based on the observations made in basic science have been established for the very common autosomal dominant polycystic kidney disease. Furthermore, the influence of genetic aspects on frequent kidney diseases, e. g. diabetic nephropathy, is becoming more obvious. This article aims to give an overview over essential recent development in the field of genetic kidney diseases.

Genetik - vererbte Nierenerkrankungen - Podozyt - Nephrotisches Syndrom - Zilien - Zystennieren - M. Fabry

genetics - inherited kidney diseases - podocyte - nephrotic syndrome - cilia - cystic kidney disease - M. Fabry

Literatur

• 1 Alamowitch S, Plaisier E, Favrole P. et al . Cerebrovascular disease related to COL4A1 mutations in HANAC syndrome.  Neurology. 2009;  73 1873-1882
• 2 Benzing T. Signaling at the slit diaphragm.  J Am Soc Nephrol. 2004;  15 1382-1391
• 3 Bostrom M A, Freedman B I, Langefeld C D. et al . Association of adiponectin gene polymorphisms with type 2 diabetes in an African American population enriched for nephropathy.  Diabetes. 2009;  58 499-504
• 4 Boyer O, Benoit G, Gribouval O. et al . Mutational analysis of the PLCE1 gene in steroid resistant nephrotic syndrome.  J Med Genet. 2010;  47 445-452
• 5 Brown E J, Schlondorff J S, Becker D J. et al . Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis.  Nat Genet. 2010;  42 72-76
• 6 Buscher A K, Kranz B, Buscher R. et al . Immunosuppression and Renal Outcome in Congenital and Pediatric Steroid-Resistant Nephrotic Syndrome.  Clin J Am Soc Nephrol. 2010;  5 2075-2084
• 7 Chambers J C, Zhang W, Lord G M. et al . Genetic loci influencing kidney function and chronic kidney disease.  Nat Genet. 2010;  42 373-375
• 8 Cochat P, Fargue S, Mestrallet G. et al . Disease recurrence in paediatric renal transplantation.  Pediatr Nephrol. 2009;  24 2097-2108
• 9 Danielsen H, Pedersen E B, Nielsen A H. et al . Expansion of extracellular volume in early polycystic kidney disease.  Acta Med Scand. 1986;  219 399-405
• 10 Fischer E, Legue E, Doyen A. et al . Defective planar cell polarity in polycystic kidney disease.  Nat Genet. 2006;  38 21-23
• 11 Fliegauf M, Benzing T, Omran H. When cilia go bad: cilia defects and ciliopathies.  Nat Rev Mol Cell Biol. 2007;  8 880-893
• 12 Freedman B I, Kopp J B, Langefeld C D. et al . The Apolipoprotein L1 (APOL1) Gene and Nondiabetic Nephropathy in African Americans.  J Am Soc Nephrol. 2010;  21 1422-1426
• 13 Friedman D J, Talbert M E, Bowden D W. et al . Functional ENTPD1 polymorphisms in African Americans with diabetes and end-stage renal disease.  Diabetes. 2009;  58 999-1006
• 14 Gaspar P, Herrera J, Rodrigues D. et al . Frequency of Fabry disease in male and female haemodialysis patients in Spain.  BMC Med Genet. 2010;  11 19
• 15 Genovese G, Friedman D J, Ross M D. et al . Association of trypanolytic ApoL1 variants with kidney disease in African Americans.  Science. 2010;  329 841-845
• 16 Gerdes J M, Davis E E, Katsanis N. The vertebrate primary cilium in development, homeostasis, and disease.  Cell. 2009;  137 32-45
• 17 Gross O, Kashtan C E. Treatment of Alport syndrome: beyond animal models.  Kidney Int. 2009;  76 599-603
• 18 Hildebrandt F. Genetic kidney diseases.  Lancet. 2010;  375 1287-1295
• 19 Hinkes B, Vlangos C, Heeringa S. et al . Specific podocin mutations correlate with age of onset in steroid-resistant nephrotic syndrome.  J Am Soc Nephrol. 2008;  19 365-371
• 20 Hinkes B G, Mucha B, Vlangos C N. et al . Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2).  Pediatrics. 2007;  119 e907-919
• 21 Huber T B, Kwoh C, Wu H. et al . Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin.  J Clin Invest. 2006;  116 1337-1345
• 22 Hudson B G, Tryggvason K, Sundaramoorthy M. et al . Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen.  N Engl J Med. 2003;  348 2543-2556
• 23 Kalluri R, Shield C F, Todd P. et al . Isoform switching of type IV collagen is developmentally arrested in X-linked Alport syndrome leading to increased susceptibility of renal basement membranes to endoproteolysis.  J Clin Invest. 1997;  99 2470-2478
• 24 Kao W H, Klag M J, Meoni L A. et al . MYH9 is associated with nondiabetic end-stage renal disease in African Americans.  Nat Genet. 2008;  40 1185-1192
• 25 Katayama K, Kawano M, Naito I. et al . Irradiation prolongs survival of Alport mice.  J Am Soc Nephrol. 2008;  19 1692-1700
• 26 Kestila M, Lenkkeri U, Mannikko M. et al . Positionally cloned gene for a novel glomerular protein-nephrin – is mutated in congenital nephrotic syndrome.  Mol Cell. 1998;  1 575-582
• 27 Knebelmann B, Kurschat C, Thadhani R. Enzyme therapy for Fabry’s disease: registered for success?.  Lancet. 2009;  374 1950-1951
• 28 Kopp J B, Smith M W, Nelson G W. et al . MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.  Nat Genet. 2008;  40 1175-1184
• 29 Kottgen A, Glazer N L, Dehghan A. et al . Multiple loci associated with indices of renal function and chronic kidney disease.  Nat Genet. 2009;  41 1191-1198
• 30 Kottgen A, Hwang S J, Larson M G. et al . Uromodulin levels associate with a common UMOD variant and risk for incident CKD.  J Am Soc Nephrol. 2010;  21 337-344
• 31 Kuusniemi A M, Qvist E, Sun Y. et al . Plasma exchange and retransplantation in recurrent nephrosis of patients with congenital nephrotic syndrome of the Finnish type (NPHS1).  Transplantation. 2007;  83 1316-1323
• 32 LeBleu V, Sugimoto H, Mundel T M. et al . Stem cell therapies benefit Alport syndrome.  J Am Soc Nephrol. 2009;  20 2359-2370
• 33 Lowik M, Levtchenko E, Westra D. et al . Bigenic heterozygosity and the development of steroid-resistant focal segmental glomerulosclerosis.  Nephrol Dial Transplant. 2008;  23 3146-3151
• 34 Machuca E, Hummel A, Nevo F. et al . Clinical and epidemiological assessment of steroid-resistant nephrotic syndrome associated with the NPHS2 R229Q variant.  Kidney Int. 2009;  75 727-735
• 35 Masyuk T V, Masyuk A I, Torres V E. et al . Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3’,5’-cyclic monophosphate.  Gastroenterology. 2007;  132 1104-1116
• 36 Mehta A, Beck M, Elliott P. et al . Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data.  Lancet. 2009;  374 1986-1996
• 37 Nishio S, Tian X, Gallagher A R. et al . Loss of oriented cell division does not initiate cyst formation.  J Am Soc Nephrol. 2010;  21 295-302
• 38 Patel V, Chowdhury R, Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease.  Curr Opin Nephrol Hypertens. 2009;  18 99-106
• 39 Pattaro C, Aulchenko Y S, Isaacs A. et al . Genome-wide linkage analysis of serum creatinine in three isolated European populations.  Kidney Int. 2009;  76 297-306
• 40 Pazour G J. Intraflagellar transport and cilia-dependent renal disease: the ciliary hypothesis of polycystic kidney disease.  J Am Soc Nephrol. 2004;  15 2528-2536
• 41 Philippe A, Nevo F, Esquivel E L. et al . Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome.  J Am Soc Nephrol. 2008;  19 1871-1878
• 42 Plaisier E, Gribouval O, Alamowitch S. et al . COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps.  N Engl J Med. 2007;  357 2687-2695
• 43 Ravine D, Gibson R N, Walker R G. et al . Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.  Lancet. 1994;  343 824-827
• 44 Reiser J, Polu K R, Moller C C. et al . TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function.  Nat Genet. 2005;  37 739-744
• 45 Schermer B, Benzing T. Lipid-protein interactions along the slit diaphragm of podocytes.  J Am Soc Nephrol. 2009;  20 473-478
• 46 Sekine T, Konno M, Sasaki S. et al . Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease.  Kidney Int. 2010;  78 207-214
• 47 Serra A L, Poster D, Kistler A D. et al . Sirolimus and kidney growth in autosomal dominant polycystic kidney disease.  N Engl J Med. 2010;  363 820-829
• 48 Shillingford J M, Murcia N S, Larson C H. et al . The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease.  Proc Natl Acad Sci U S A. 2006;  103 5466-5471
• 49 Shillingford J M, Piontek K B, Germino G G. et al . Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.  J Am Soc Nephrol. 2010;  21 489-497
• 50 Spada M, Pagliardini S, Yasuda M. et al . High incidence of later-onset fabry disease revealed by newborn screening.  Am J Hum Genet. 2006;  79 31-40
• 51 Srivastava T, Garola R E, Kestila M. et al . Recurrence of proteinuria following renal transplantation in congenital nephrotic syndrome of the Finnish type.  Pediatr Nephrol. 2006;  21 711-718
• 52 Sugimoto H, Mundel T M, Sund M. et al . Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease.  Proc Natl Acad Sci U S A. 2006;  103 7321-7326
• 53 Torres V E, Harris P C. Autosomal dominant polycystic kidney disease: the last 3 years.  Kidney Int. 2009;  76 149-168
• 54 van Keimpema L, Nevens F, Vanslembrouck R. et al . Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.  Gastroenterology. 2009;  137 1661-1668 e1661 – 1662
• 55 Walz G, Budde K, Mannaa M. et al . Everolimus in patients with autosomal dominant polycystic kidney disease.  N Engl J Med. 2010;  363 830-840
• 56 Winn M P, Conlon P J, Lynn K L. et al . A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis.  Science. 2005;  308 1801-1804
• 57 Yoder B K, Richards W G, Sweeney W E. et al . Insertional mutagenesis and molecular analysis of a new gene associated with polycystic kidney disease.  Proc Assoc Am Physicians. 1995;  107 314-323
• 58 Zenker M, Machuca E, Antignac C. Genetics of nephrotic syndrome: new insights into molecules acting at the glomerular filtration barrier.  J Mol Med. 2009;  87 849-857